Establishment Labs expands minimally invasive breast systems and shares tissue preservation data at global symposium

The scientific content included a four-part, peer-reviewed supplement published in the Aesthetic Surgery Journal titled Breast Tissue Preservation Building Blocks. More than 25 contributors — including board-certified plastic and reconstructive surgeons, anatomists, pathologists, and academic researchers — authored material that covered breast anatomy, the foundations and rationale for tissue-preserving techniques, and early- to mid-term clinical data on the company's Minimally Invasive Platform.

Symposium sessions also reviewed the first published US multicenter clinical experience with Preserve. Establishment Labs framed this research as establishing an anatomical and scientific foundation intended to supply surgeons with a standardized framework to preserve breast anatomy while minimizing tissue disruption.

Troy Pittman, a board-certified plastic surgeon and author, described the publication as establishing a foundation for tissue preservation and said Preserve and the building blocks of Breast Tissue Preservation changed his practice and approach. Peter Caldini, CEO of Establishment Labs, said the platform's commercial success accelerated plans to bring expanded sizes to market and that the company is working on additional product launches to broaden its minimally invasive portfolio.

Establishment Labs announced product line extensions: new sizes and supporting tools for both the Mia and Preserve systems. The company said these additions aim to expand candidate eligibility as demand for minimally invasive breast procedures rises.

Market context cited by the company

What this means for surgeons and patients

For surgeons: the peer-reviewed supplement and multicenter data provide a documented set of anatomical and technical material to reference when evaluating tissue-preserving techniques. The new sizes and tools may allow surgeons to offer minimally invasive options to a broader set of patients.

For patients: the expanded sizes could increase eligibility for minimally invasive augmentation, potentially offering options that aim to reduce tissue disruption. The clinical publications and multicenter experience provide early- and mid-term data surgeons can use when discussing technique and outcomes with patients.

Establishment Labs combined product updates with a concentrated effort to publish and present scientific work on breast tissue preservation. The company framed the developments as both a clinical-scientific advance — via the Aesthetic Surgery Journal supplement and multicenter data — and a commercial expansion, with new sizes and planned launches intended to widen patient access to minimally invasive breast augmentation.